| Literature DB >> 29850029 |
Steven Blackburn1, Sarah McLachlan2, Sue Jowett3, Philip Kinghorn3, Paramjit Gill4, Adele Higginbottom1,5, Carol Rhodes1,5, Fiona Stevenson6, Clare Jinks1.
Abstract
PLAIN ENGLISHEntities:
Keywords: Cost and consequences framework; Impact; Mixed methods, primary care research; Patient and public involvement; Quality
Year: 2018 PMID: 29850029 PMCID: PMC5966874 DOI: 10.1186/s40900-018-0100-8
Source DB: PubMed Journal: Res Involv Engagem ISSN: 2056-7529
Types of data extracted from the project documentation
| • Study design |
The principles and indicators of successful consumer involvement in NHS research. Adapted from Boote et al. [25]
| Principle | Indicator(s) |
|---|---|
| 1. The roles of consumers are agreed between the researchers and consumers involved in the research | The roles of consumers in the research were documented |
| 2. Researchers budget appropriately for the costs of consumer involvement in research | Researchers applied for funding to involve consumers in the research |
| Consumers were reimbursed for their travel costs | |
| Consumers were reimbursed for their indirect costs (e.g. carer costs) | |
| 3. Researchers respect the differing skills, knowledge and experience of consumers | The contribution of consumers’ skills, knowledge and experience were included in research reports and papers |
| 4. Consumers are offered training and personal support, to enable them to be involved in research | Consumers’ training needs related to their involvement in the research were agreed between consumers and researchers |
| Consumers had access to training to facilitate their involvement in the research | |
| Mentors were available to provide personal and technical support to consumers | |
| 5. Researchers ensure that they have the necessary skills to involve consumers in the research process | Researchers ensured that their own training needs were met in relation to involving consumers in the research |
| 6. Consumers are involved in decisions about how participants are both recruited and kept informed about the progress of the research | Consumers gave advice to researchers on how to recruit participants to the research |
| Consumers gave advice to researchers on how to keep participants informed about the progress of the research | |
| 7. Consumer involvement is described in research reports | The involvement of consumers in the research reports and publications was acknowledged |
| Details were given in the research reports and publications of how consumers were involved in the research process | |
| 8. Research findings are available to consumers, in formats and in language they can easily understand | Research findings were disseminated to consumers involved in the research in appropriate formats (e.g. large print, translations, audio, Braille) |
| The distribution of the research findings to relevant consumer groups was in appropriate formats and easily understandable language | |
| Consumers involved in the research gave their advice on the choice of methods used to distribute the research findings |
PPI in SPCR projects, by study design, health condition, population and population age
| Projects (Grant applications) | Projects with evidence of PPI in developing the grant application | Projects with evidence of plans for PPI during the study in the grant application ( | Projects (Annual/ Final Reports)a | Projects with evidence of PPI reported in annual/final reports ( | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| n | (%) | n | (%) | (Relative %)b | n | (%) | (Relative %)b | n | (%) | n | (%) | (Relative %)c | |
| All Projects | 200 | (100) | 47 | (23.5) | 113 | (56.5) | 181 | (181) | 83 | (46.1) | |||
| Study Design | |||||||||||||
| Mixed methods | 47 | (23.5) | 15 | (7.5) | (31.9) | 30 | (15.0) | (63.8) | 39 | (21.5) | 24 | (13.3) | (61.5) |
| Qualitative | 36 | (18.0) | 9 | (4.5) | (25.0) | 23 | (11.5) | (63.9) | 30 | (16.6) | 17 | (9.4) | (56.7) |
| Longitudinal cohort | 29 | (14.5) | 5 | (2.5) | (17.2) | 18 | (9.0) | (62.1) | 29 | (16.0) | 11 | (6.1) | (37.9) |
| Intervention trial | 25 | (12.5) | 6 | (3.0) | (24.0) | 15 | (7.5) | (60.0) | 23 | (12.7) | 14 | (7.7) | (60.9) |
| Systematic reviews | 17 | (8.5) | 2 | (1.0) | (11.8) | 7 | (3.5) | (0.0) | 17 | (9.4) | 2 | (1.1) | (11.8) |
| Retrospective cohort | 13 | (6.5) | 2 | (1.0) | (15.4) | 4 | (2.0) | (30.8) | 13 | (7.2) | 3 | (1.7) | (23.1) |
| Secondary analysis | 8 | (4.0) | 0 | (0.0) | (0.0) | 4 | (2.0) | (50.0) | 8 | (4.4) | 3 | (1.7) | (37.5) |
| Cross sectional | 7 | (3.5) | 4 | (2.0) | (57.1) | 3 | (1.5) | (42.9) | 7 | (3.9) | 4 | (2.2) | (57.1) |
| Methodological | 5 | (2.5) | 1 | (0.5) | (20.0) | 4 | (2.0) | (80.0) | 4 | (2.2) | 1 | (0.6) | (25.0) |
| Case control | 4 | (2.0) | 0 | (0.0) | (0.0) | 1 | (0.5) | (25.0) | 3 | (1.7) | 0 | 0 | (0.0) |
| Multi-stage studyd | 4 | (2.0) | 2 | (1.0) | (50.0) | 2 | (1.0) | (50.0) | 2 | (1.1) | 2 | (1.1) | (100) |
| Individual participant meta analysis | 3 | (1.5) | 0 | (0.0) | (0.0) | 1 | (0.5) | (33.3) | 2 | (1.1) | 1 | (0.6) | (50.0) |
| Othere | 2 | (1.0) | 1 | (0.5) | (50.0) | 1 | (0.5) | (50.0) | 4 | (2.2) | 2 | (1.1) | (50.0) |
| Health Condition Under Study | |||||||||||||
| General Health | 28 | (14.0) | 9 | (4.5) | (32.1) | 14 | (7.0) | (50.0) | 22 | (12.2) | 9 | (0.0) | (40.9) |
| Cardiovascular | 27 | (13.5) | 4 | (2.0) | (14.8) | 16 | (8.0) | (59.3) | 28 | (15.5) | 10 | (5.5) | (35.7) |
| Mental Health | 21 | (10.5) | 5 | (2.5) | (23.8) | 12 | (6.0) | (57.1) | 17 | (9.4) | 11 | (6.1) | (64.7) |
| Cancer | 16 | (8.0) | 7 | (3.5) | (43.8) | 8 | (4.0) | (50.0) | 16 | (8.8) | 10 | (5.5) | (62.5) |
| Metabolic and Endocrine | 14 | (7.0) | 1 | (0.5) | (7.1) | 6 | (3.0) | (42.9) | 16 | (8.8) | 9 | (5.0) | (56.3) |
| Musculoskeletal | 14 | (7.0) | 3 | (1.5) | (21.4) | 6 | (3.0) | (42.9) | 13 | (7.2) | 6 | (3.3) | (46.2) |
| Respiratory | 13 | (6.5) | 3 | (1.5) | (23.1) | 6 | (3.0) | (46.2) | 12 | (6.6) | 5 | (2.8) | (41.7) |
| Multimorbidity | 7 | (3.5) | 0 | (0.0) | (0.0) | 1 | (0.5) | (14.3) | 8 | (4.4) | 3 | (1.7) | (37.5) |
| Stroke | 7 | (3.5) | 1 | (0.5) | (14.3) | 3 | (1.5) | (42.9) | 5 | (2.8) | 2 | (1.1) | (40.0) |
| Infection | 5 | (2.5) | 1 | (0.5) | (20.0) | 3 | (1.5) | (60.0) | 5 | (2.8) | 1 | (5.0) | (20.0) |
| Renal and Urogenital | 5 | (2.5) | 2 | (1.0) | (40.0) | 5 | (2.5) | (100) | 5 | (2.8) | 3 | (1.7) | (60.0) |
| Reproductive Health and Childbirth | 5 | (2.5) | 2 | (1.0) | (40.0) | 5 | (2.5) | (100) | 5 | (2.8) | 4 | (2.2) | (80.0) |
| Neurological | 3 | (1.5) | 0 | (0.0) | (0.0) | 3 | (1.5) | (100) | 1 | (0.6) | 1 | (0.6) | (100) |
| Cancer, Mental Health | 1 | (0.5) | 1 | (0.5) | (100) | 0 | (0.0) | (0.0) | 1 | (0.6) | 1 | (0.6) | (100) |
| Inflammatory and Immune System | 1 | (0.5) | 0 | (0.0) | (0.0) | 0 | (0.0) | (0.0) | 0 | (0.0) | 0 | (0.0) | |
| Oral and Gastrointestinal | 1 | (0.5) | 0 | (0.0) | (0.0) | 0 | (0.0) | (0.0) | 1 | (0.6) | 0 | (0.0) | (0.0) |
| Skin | 1 | (0.5) | 1 | (0.5) | (100) | 1 | (0.5) | (100) | 1 | (0.6) | 1 | (0.6) | (100) |
| Otherf | 31 | (15.5) | 7 | (3.5) | (22.6) | 24 | (12.0) | (77.4) | 23 | (12.7) | 8 | (4.4) | (34.8) |
| Study population | |||||||||||||
| Patients | 134 | (67.0) | 26 | (13.0) | (19.4) | 68 | (34.0) | (50.7) | 123 | (68.0) | 54 | (29.8) | (43.9) |
| Patients & HCPs | 37 | (18.5) | 11 | (5.5) | (29.7) | 24 | (12.0) | (64.9) | 31 | (17.1) | 20 | (11.0) | (64.5) |
| Healthcare professionals (HCPs) | 15 | (7.5) | 5 | (2.5) | (33.3) | 10 | (5.0) | (66.7) | 8 | (4.4) | 3 | (1.7) | (37.5) |
| General public | 13 | (6.5) | 5 | (2.5) | (38.5) | 10 | (5.0) | (76.9) | 15 | (8.3) | 7 | (3.9) | (46.7) |
| Carers | 1 | (0.5) | 0 | (0.0) | (0.0) | 1 | (0.5) | (100) | 1 | (0.6) | 0 | (0.0) | (0.0) |
| Study population age | |||||||||||||
| Unspecified | 93 | (46.5) | 19 | (9.5) | (20.4) | 54 | (27.0) | (58.1) | 83 | (45.9) | 35 | (19.9) | (43.4) |
| Adult (18+ years) | 89 | (44.5) | 24 | (12.0) | (27.0) | 50 | (25.0) | (56.2) | 83 | (45.9) | 42 | (23.2) | (50.6) |
| Adult and Children | 11 | (5.5) | 4 | (2.0) | (36.4) | 7 | (3.5) | (63.6) | 9 | (5.0) | 5 | (2.8) | (55.6) |
| Children and young adults (0–17 years)g | 7 | (3.5) | 0 | (0.0) | (0.0) | 2 | (1.0) | (28.6) | 6 | (3.3) | 1 | (0.6) | (16.7) |
aIncluded one project whose data on PPI was obtained from an SPCR poster
bPercentage relative to the number of projects in each category in grant applications
cPercentage relative to the number of projects in each category in annual/final reports
dMulti-stage studies included case control and intervention trial (1), cross sectional and longitudinal cohort (1), systematic review and longitudinal cohort (1), systematic review and secondary analysis
eIncluded projects to set up and maintain a SPCR PPI group (1) and a preliminary descriptive study (1)
fConditions not classified under the Health Research Classification System [24]
gIt was not always possible to determine the ages or age range of children from the study documentation. Sometimes, ages were provided, sometimes the documentation referred to ‘children’. So we have assumed children and young adults to be 17 and under
Fig. 1Evidence of PPI in SPCR funded project grant applications and annual/final reports by funding round (N = 200). * Details of the respective funding rounds was unavailable for 18 projects
Fig. 2The nature of PPI planned in SPCR project proposals and reported in annual/final reports
Fig. 3Consistency of PPI activities reported in annual/final reports compared to the plans for PPI within the project proposal (N = 179)
Fig. 4Levels of best practice for PPI in SPCR projects, according to Boote et al’s quality indicators [25]. ^ Combination of two quality indicators linked with expenses: travel costs and indirect costs (e.g. carer costs); * Combines three quality indicators: ‘contribution of PPI included in research reports and papers’, ‘PPI acknowledged in research reports and papers’ and ‘details of PPI reported in research reports and publications’. Data obtained from a PubMed search for articles associated with the 15 projects included in the analysis; # Adaptation of the quality indicator: ‘PPI offered mentors for personal and technical support’; $ Adaptation of the quality indicator: ‘Research findings were distributed to patients involved in the research in an appropriate format’
Fig. 5Quality-Impact Index scores: The association between the Quality Score (number of quality indicators met by a project) and the Impact Score (number of PPI activities which the PI reported a perceived impact)
Costs and Consequences Framework
| Impact upon | Costs (−) | Benefits (+) | |
|---|---|---|---|
| Researcher | |||
| Research Project | Shaping the research question and maintaining focus | ||
| Research methods/design | |||
| Recruitment & recruitment materials | |||
| Conducting & managing research | |||
| Commenting on results | |||
| Dissemination |
| ||
| Generating new research questions (expanding upon current research) | |||
| Research Institution | |||
| Funder | |||
| PPI contributors |
|
| |
Entries in italics were identified from the literature but not verified by respondents
a Sometimes included within the direct payment
Recommendations for improving the practice and delivery of PPI in research
| Key Findings | Recommendations for improving PPI in research |
|---|---|
| Best Practice | |
| A. Overall PPI in research was low and inconsistent across research design and topics | 1. Promote PPI as a core research function in all research by raising awareness of its value and impact |
| B. PPI was mostly limited to a few activities in the research cycle | 2. Identify and share good examples of PPI activity across the research cycle to improve range and quality of PPI in future funded projects |
| C. ‘Best Practice’ was inconsistent | 4. Create dedicated champion(s) for PPI within research institutions to promote best practice |
| D. Time to do PPI is the biggest consequence to researchers | 11. Raise awareness of time commitment for meaningful PPI so researchers can plan for it effectively |
| E. PPI is good for research and researchers | 12. Continue to showcase and celebrate the impact of PPI in research |
| SPCR Systems and Processes | |
| A. Overall PPI activity in research was low | 13. Increase the overall PPI activity in SPCR projects, by developing networks for PPI groups and researchers, and encouraging sustainable processes and infrastructure for PPI |
| B. PPI was mostly limited to a few activities in the research cycle | 14. Increase the range of appropriate PPI in SPCR funded research, by providing more guidance and support to researchers and grant reviewers |
| C. PPI is poorly recorded and reported | 15. Improve the recording and reporting of PPI in SPCR to promote transparency, support diversity and enable the evaluation of impact by improving reporting form templates and better monitoring of PPI in SPCR activities and funded research |
Experience of lay co-applicants and co-authors (CR, AH) regarding their involvement in this study and its findings
| CR: “As a lay coordinator of a growing group of research users involved in a variety of primary care research projects across a clinical trials unit, I was very aware of the varied approaches to PPI being undertaken both regionally and nationally. So I was very interested in being involved in a project looking at PPI within a group of projects across one funder, looking particularly at the costs and benefits of PPI to the patients and the researchers, as not all costs are quantifiable and those that are, are not routinely recorded. Yet in my experience many patients and researchers go above and beyond what is asked of them, because they sincerely believe that patient involvement is an absolute must for good rigorous primary care research that can go on to be implemented to improve patients’ daily care. I was also keen to be involved in looking at the results and how they could be used to inform PPI practice for the future. |